Who Adopts Agentic AI for GMP Documents First?

Who adopts agentic AI for GMP documents first: Big Pharma or SMEs? And who benefits more in the long run?

The intuitive answer is Big Pharma: big budgets, large QA teams, more documents to produce. But incentives point the other way. Big Pharma carries sunk cost in validated legacy systems and risk committees that treat any process change as a threat first.

SMEs face the opposite situation. A small manufacturer is subject to the same regulatory requirements as a large one. For them, GMP documents prepared by a validated process built on agentic AI do not only decrease costs but also free QA capacity for value-creating activities.

First mover and long-term winner may not be the same party. The early adopter takes the risk. Who captures the durable advantage is a separate question. We'll find out the answer soon.